BORTEZOM 2MG INJECTION contains Bortezomib which belongs to the group of medicines called Antineoplastic agents. It is used in adult patients alone or with pegylated liposomal doxorubicin/dexamethasone to treat progressive multiple myeloma when anticancer therapy or hematopoietic stem cell transplantation becomes unsuitable to treat the disease.
BORTEZOM 2MG INJECTION is also used in adult patients with rituximab, cyclophosphamide, doxorubicin and prednisone to treat untreated mantle cell lymphoma when hematopoietic stem cell transplantation becomes unsuitable to treat the disease.
Multiple myeloma is a type of cancer that occurs in plasma cells (white blood cells) which are generally characterized by symptoms such as bone pain, nausea, constipation and loss of appetite. Mantle Cell Lymphoma is a rare form of cancer that affects the lymphatic system, generally characterized by symptoms such as loss of appetite, fever, nausea and/or vomiting.
Your doctor may advise you to do regular blood tests to check your blood counts before and during treatment with BORTEZOM 2MG INJECTION. It is not recommended for use in patients with severe lung or heart disease.
BORTEZOM 2MG INJECTION is not recommended for use in pregnant and breastfeeding women. BORTEZOM 2MG INJECTION is also not indicated for use in children and adolescents (below 18 years of age).
The most common side effects of receiving BORTEZOM 2MG INJECTION are dizziness, increased heartbeat, sweating, abnormal vision, paresthesia (burning or pickling sensation), muscle pain and headache. Inform your doctor if any of the symptoms worsen during or after treatment with BORTEZOM 2MG INJECTION.
Used in adults:
BORTEZOM 2MG INJECTION works by inhibiting proteasomes (enzymes responsible for breaking down proteins into smaller compounds for cells) which leads to an imbalance in the cancer cell thus resulting in its destruction and thereby treating multiple myeloma and mantle cell lymphoma in affected individuals.
BORTEZOM 2MG INJECTION will be given to you only by a doctor or a nurse into a vein as an intravenous infusion or into skin as a subcutaneous injection. Your doctor will decide the correct dose and duration of BORTEZOM 2MG INJECTION for you depending upon your age, body weight and disease condition.
Stop receiving BORTEZOM 2MG INJECTION and contact your doctor immediately if you experience any of the following side effects:
Headache:
Rest and relax. Drink plenty of fluids such as water or electrolytes. Apply a pain-relieving balm on the head if required. Do not consume alcohol. Inform your doctor if the symptom did not improve.
Diarrhoea:
Drink lot of fluids such as water or fruit juices to keep yourself hydrated. Inform your doctor if the symptom did not improve.
Nausea:
Stick to simple meals. Avoid eating oil-rich or spicy foods. Inform your doctor if the symptom did not improve.
Stomach Pain:
Try to rest and relax. Eat and drink slowly or try to have smaller and more frequent meals. Keep a heating pad on your stomach. If the symptom does not improve, contact your doctor.
Constipation:
Eat more fibre foods, especially soluble fibres. Keep yourself hydrated. Inform your doctor if the symptom did not improve.
BORTEZOM 2MG INJECTION is not recommended for use during pregnancy and in women planning for pregnancy. It should be used with caution in women with childbearing potential who should use effective contraceptive measures before receiving BORTEZOM 2MG INJECTION.
BORTEZOM 2MG INJECTION is not recommended for use in breastfeeding women. Consult your doctor before receiving BORTEZOM 2MG INJECTION.
Do not drive or operate any machines if you feel dizzy, tired, syncope (fainting), and/or blurred vision after receiving BORTEZOM 2MG INJECTION.
BORTEZOM 2MG INJECTION should be used with caution in patients with kidney problems such as mild to moderate renal impairment. Consult your doctor before receiving BORTEZOM 2MG INJECTION.
BORTEZOM 2MG INJECTION should be used with caution in patients with moderate or severe liver problems such as hepatic impairment. Consult your doctor before receiving BORTEZOM 2MG INJECTION.
Do not receive BORTEZOM 2MG INJECTION if you are allergic to bortezomib, boron or any other ingredients of this medicine. Consult your doctor before receiving BORTEZOM 2MG INJECTION.
BORTEZOM 2MG INJECTION is not recommended for use in patients with severe lung problems. It should be used with caution in patients with hepatitis B virus disease. Consult your doctor before receiving BORTEZOM 2MG INJECTION.
BORTEZOM 2MG INJECTION is not recommended for use if you have severe heart problems. BORTEZOM 2MG INJECTION should be used with caution in patients suffering from heart problems such as congestive heart failure. Consult your doctor before receiving BORTEZOM 2MG INJECTION.
Before receiving BORTEZOM 2MG INJECTION, inform your doctor if you have:
Use in Pediatrics:
BORTEZOM 2MG INJECTION is generally not recommended for use in children and adolescents (aged below 18 years). Consult your child’s doctor for advice before administration of BORTEZOM 2MG INJECTION to your child.
Use in Geriatrics:
BORTEZOM 2MG INJECTION should be used with caution in elderly patients (aged 65 years and above). Consult your doctor before receiving BORTEZOM 2MG INJECTION.
A. Drug - Drug interactions:
Before taking BORTEZOM 2MG INJECTION, inform your doctor if you are taking any of the following medicines:
Overdosage:
BORTEZOM 2MG INJECTION will be administered to you only by a doctor or a nurse in a hospital, and so it is unlikely to receive an overdose. However, consult your doctor if you experience any unusual symptoms of BORTEZOM 2MG INJECTION such as acute onset of symptomatic hypotension (low blood pressure while standing up from lying position) and thrombocytopenia (condition marked with low platelet count).
Drug | : | Bortezomib |
Pharmacological Category | : | Anti-neoplastic agent |
Therapeutic Indication | : | Multiple myeloma, Mantle cell lymphoma |
Dosage Forms | : | Injection |
How is BORTEZOM 2MG INJECTION administered?
BORTEZOM 2MG INJECTION will be given to you only by a doctor or a nurse into a vein as an intravenous infusion or into skin as a subcutaneous injection. Your doctor will decide the correct dose and duration of BORTEZOM 2MG INJECTION for you depending upon your age, body weight and disease condition.
Can BORTEZOM 2MG INJECTION be used during pregnancy?
BORTEZOM 2MG INJECTION is not recommended for use during pregnancy and in women planning for pregnancy. It should be used with caution in women with childbearing potential who should use effective contraceptive measures before receiving BORTEZOM 2MG INJECTION.
Who should avoid receiving BORTEZOM 2MG INJECTION?
BORTEZOM 2MG INJECTION is not recommended for use in patients with severe lung and liver problems which is also not recommended for use in pregnant and breastfeeding women. BORTEZOM 2MG INJECTION is also not indicated for use in children and adolescents (below 18 years of age). Consult your doctor before receiving BORTEZOM 2MG INJECTION.
Can I drive after receiving BORTEZOM 2MG INJECTION?
Do not drive after receiving BORTEZOM 2MG INJECTION since it may cause dizziness, tiredness, syncope (fainting) and/or blurred vision which may affect your ability/concentration to drive. Consult your doctor before receiving BORTEZOM 2MG INJECTION.
Can BORTEZOM 2MG INJECTION be used in patients with liver problems?
BORTEZOM 2MG INJECTION should be used with caution in patients with moderate or severe liver problems such as hepatic impairment. Consult your doctor before receiving BORTEZOM 2MG INJECTION.
1. Lawrence. L. Brunton. John S. Lazo, Keith L.Parker. Chemotherapy of Neoplastic drugs. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 2018 Page 1372.
2. Antonia Field-Smith, Gareth J Morgan, and Faith E Davies. Bortezomib (Velcade) in the Treatment of Multiple Myeloma. NIH National Library of Medicine, National center for biotechnology information. Pubmed Central. September 2006. [Accessed on 4th May 2022] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936263/
3. Dana-Farber Cancer Institute. Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma. NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised in June 2019] [Accessed on 4th May 2022] https://www.clinicaltrials.gov/ct2/show/NCT00153920
4. Accord Healthcare B.V. European Medical Agency (EMA). [Revised July 2021] [Accessed on 4th May 2022] https://www.ema.europa.eu/en/documents/product-information/bortezomib-accord-epar-product-information_en.pdf
5. Arecher Healthcare LLP. Bortezomib Injection. [Accessed on 4th May 2022] https://www.arechar.in/blog/bortecine-bortezomib-injection
Written By Dr. R. Dinesh John Rajkumar, Pharm.D
Last updated on 16 Aug 2023 | 05:51 PM(IST)
The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.